Stockscreener 앱 받기
237.30
1.41%
3.16
Resmed Inc 주식(RMD)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
ResMed Inc. Files Quarterly Report, Reinforces Market Position - MSN
ASX healthcare leader continues to prove the doubters wrong - Morningstar
What does Macquarie think ResMed shares are worth? - MSN
ResMed brushes off tariff threat - Intelligent Investor
ResMed Q1 2025: Strong Sales Growth and Strategic InitiativesNews and Statistics - IndexBox
ResMed Inc. (NYSE:RMD) Q3 2025 Earnings Call Transcript - Insider Monkey
ResMed Inc’s Earnings Call Highlights Growth and Innovation - TipRanks
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Decoding ResMed Inc (RMD): A Strategic SWOT Insight - GuruFocus
ResMed Inc. stock rises Thursday, outperforms market - MSN
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast - Benzinga
ResMed (NYSE:RMD) Reports Strong Q3 Earnings Growth and Declares US$0.53 Dividend - Yahoo Finance
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates - MSN
ResMed Inc (RMD) Shares Up 11.28% on Apr 24 - GuruFocus
ResMed price target raised to $255 from $247 at RBC Capital - TipRanks
Jefferies Adjusts Price Target on ResMed to $245 From $270, Maintains Hold Rating - marketscreener.com
Morgan Stanley Adjusts Price Target on ResMed to $286 From $280, Maintains Overweight Rating - marketscreener.com
ResMed stock holds as Oppenheimer maintains Perform rating By Investing.com - Investing.com Canada
Texas Instruments Posts Better-Than-Expected Results, Joins Community Health Systems, Hasbro, ServiceNow, ResMed And Other Big Stocks Moving Higher On ThursdayArdagh Metal Packaging (NYSE:AMBP), Allegion (NYSE:ALLE) - Benzinga
Stifel maintains ResMed stock hold rating and $240 target - Investing.com
Stifel maintains ResMed stock hold rating and $240 target By Investing.com - Investing.com UK
ResMed Inc (RMD)'s Winning Formula: Financial Metrics and Compet - GuruFocus
ResMed stock price target raised to $255 at RBC Capital - Investing.com
Piper Sandler cuts ResMed stock price target to $248 - Investing.com
Piper Sandler cuts ResMed stock price target to $248 By Investing.com - Investing.com UK
ResMed (RMD) Target Price Lowered by Piper Sandler Following Ear - GuruFocus
ResMed (RMD) Price Target Reduced by Mizuho | RMD Stock News - GuruFocus
Mizuho cuts ResMed stock price target to $250 from $265 By Investing.com - Investing.com India
Mizuho cuts ResMed stock price target to $250 from $265 - Investing.com
ResMed (RMD) Target Price Lowered by Piper Sandler Following Earnings | RMD Stock News - GuruFocus
RBC Capital Lifts ResMed (RMD) Price Target Amid Solid Q3 Performance | RMD Stock News - GuruFocus
ResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets - Morningstar
RBC Raises Price Target on ResMed to $255 From $247, Keeps Sector Perform Rating - marketscreener.com
ResMed stock holds as Oppenheimer maintains Perform rating - Investing.com India
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market - Yahoo Finance
KeyBanc Boosts ResMed (RMD) Price Target Amid Positive Q3 Outlook | RMD Stock News - GuruFocus
ResMed (RMD) Announces Consistent Quarterly Dividend - GuruFocus
Why Liontown, Newmont, Paladin Energy, and ResMed shares are charging higher today - MSN
RESMED INC SEC 10-Q Report - TradingView
ResMed: Cornering The Market In Sleep Solutions - Seeking Alpha
ResMed: Fiscal Q3 Earnings Snapshot - MySA
ResMed Inc (RMD) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Earnings call transcript: ResMed Q3 2025 beats revenue forecast - Investing.com
ResMed Inc (RMD) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
ResMed Inc (RMD) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments Propel Performance - GuruFocus
Resmed Inc. Reports Strong Q3 2025 Earnings - TipRanks
ResMed stock gains as tariff exemptions boost US manufacturing strategy - ig.com
ResMed shares jump 8% on strong Q3 update - MSN
ResMed delivers double-digit EPS growth on increasing demand for sleep apnoea devices - TradingView
Health Check: Snore-buster Resmed says miracle diet drugs and tariffs no threat to growth - Stockhead
ResMed Inc Shares Surge Amid Strong Financial Results - TipRanks
ResMed slightly beats quarterly profit estimates, shrugs tariff concerns - MSN
Here's What Key Metrics Tell Us About ResMed (RMD) Q3 Earnings - MSN
Resmed Inc. Achieves Strong Q3 2025 Financial Results with 8% Revenue Growth - TipRanks
ResMed Q3 FY2025 presentation: Revenue hits $1.29B as digital health strategy advances - Investing.com Australia
ResMed posts Street-beating Q3 - MassDevice
0.59%
자본화:
|
볼륨(24시간):